- Tous > Medicine Information and Evidence for Policy > Medicines Policy
- Tous > Medicine Access and Rational Use > Antimicrobial Drug Resistance
- Tous > Public Health, Innovation, Intellectual Property and Trade > Research and Development (R&D) - Innovation and Financing
- Mots-clés > antibiotic policy
- Mots-clés > antibiotic resistance
- Mots-clés > antimicrobial resistance (AMR)
- Mots-clés > antimicrobials
- Mots-clés > pharmaceutical gaps
- Mots-clés > pharmaceutical industry - incentive for R&D
- Mots-clés > pharmaceutical innovation
- Mots-clés > pharmaceutical research - priorities
- Mots-clés > priority diseases
- Mots-clés > priority medicines
(2016; 133 pages)
Antimicrobial resistance is a global crisis that threatens public health and modern medicine. Discovery and development of novel antibiotic products is a critical component to combating antimicrobial resistance. Numerous initiatives operate at international, European Union and national levels to address the scientific, regulatory and economic barriers to antibiotic innovation.
This study identifies, reviews and critically assesses these initiatives, and ultimately provides a set of policy recommendations for improving the global and European research and development agenda for antibiotics.